Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Allogene Therapeutics, Inc. | SVP, General Counsel | Common Stock | 449K | $1.25M | $2.79 | Aug 21, 2024 | Direct |
Allogene Therapeutics, Inc. | SVP, General Counsel | Stock Option (Right to buy) | 148K | Jan 25, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ALLO | Allogene Therapeutics, Inc. | Aug 21, 2024 | 1 | -$78.8K | 4 | Aug 23, 2024 | SVP, General Counsel |
ALLO | Allogene Therapeutics, Inc. | Jan 25, 2024 | 2 | $0 | 4 | Jan 31, 2024 | SVP, General Counsel |
ALLO | Allogene Therapeutics, Inc. | Aug 14, 2023 | 3 | $0 | 4 | Aug 17, 2023 | GENERAL COUNSEL |
ALLO | Allogene Therapeutics, Inc. | Aug 14, 2023 | 0 | $0 | 3 | Aug 17, 2023 | GENERAL COUNSEL |